Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData, Phase II drugs for Metastatic Uveal Melanoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Defactinib hydrochloride LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Defactinib hydrochloride overview

Defactinib hydrochloride (VS-6063) is under development for the treatment of pancreatic ductal adenocarcinoma as adjuvant therapy, metastatic uveal melanoma, KRAS-mutated NSCLC, colorectal cancer, malignant pleural mesothelioma, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, endometrial cancer, prostate cancer, epithelial ovarian cancer, fallopian tube cancer, low-grade serous ovarian cancer, peritoneal cancer, triple negative breast cancer, recurrent glioblastoma multiforme and pancreatic cancer. The drug candidate is administered by oral route. VS-6063 is a selective inhibitor of the focal adhesion kinase (FAK1) or protein tyrosine kinase 2 (PTK-2). It was also under development for malignant pleural mesothelioma in EU and solid tumors (non-hematologic malignancy).

Verastem overview

Verastem is a biopharmaceutical company. It carries out the discovery, development, and commercialization of novel small molecule drugs to treat cancer. The company’s most advanced product candidates include VS-6766, defactinib (VS-6063). Verastem products VS-6766 and defactinib (VS-6063), are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. The pipeline products focused on RAF/MEK inhibition and FAK inhibition. Its service include investigator sponsored trial (IST)program. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.

For a complete picture of Defactinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.